OLD Mission Capital LLC Buys New Position in Genmab A/S (NASDAQ:GMAB)

OLD Mission Capital LLC purchased a new position in shares of Genmab A/S (NASDAQ:GMAB) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm purchased 111,601 shares of the company’s stock, valued at approximately $2,329,000.

A number of other hedge funds and other institutional investors have also modified their holdings of the company. Charles Schwab Investment Management Inc. boosted its position in Genmab A/S by 94.1% during the third quarter. Charles Schwab Investment Management Inc. now owns 26,104 shares of the company’s stock worth $636,000 after acquiring an additional 12,654 shares during the last quarter. Cerity Partners LLC lifted its stake in shares of Genmab A/S by 14.6% during the 3rd quarter. Cerity Partners LLC now owns 48,003 shares of the company’s stock worth $1,170,000 after purchasing an additional 6,103 shares during the period. FMR LLC boosted its holdings in shares of Genmab A/S by 13.5% during the third quarter. FMR LLC now owns 278,194 shares of the company’s stock worth $6,782,000 after purchasing an additional 33,076 shares during the last quarter. Verition Fund Management LLC purchased a new stake in shares of Genmab A/S in the third quarter valued at $709,000. Finally, HighTower Advisors LLC acquired a new position in Genmab A/S in the third quarter valued at $273,000. 7.07% of the stock is currently owned by hedge funds and other institutional investors.

Genmab A/S Trading Down 4.7 %

Shares of Genmab A/S stock opened at $18.66 on Wednesday. Genmab A/S has a twelve month low of $18.50 and a twelve month high of $30.50. The stock has a market cap of $12.35 billion, a price-to-earnings ratio of 10.72, a price-to-earnings-growth ratio of 2.65 and a beta of 0.98. The company has a fifty day moving average price of $20.81 and a 200 day moving average price of $21.73.

Genmab A/S (NASDAQ:GMAB) last issued its earnings results on Wednesday, February 12th. The company reported $0.57 earnings per share for the quarter, topping the consensus estimate of $0.28 by $0.29. Genmab A/S had a return on equity of 16.78% and a net margin of 36.30%. Analysts forecast that Genmab A/S will post 1.45 earnings per share for the current year.

Analysts Set New Price Targets

GMAB has been the topic of a number of research analyst reports. BNP Paribas raised Genmab A/S from a “strong sell” rating to a “hold” rating in a research note on Tuesday, February 11th. Truist Financial decreased their target price on shares of Genmab A/S from $50.00 to $45.00 and set a “buy” rating on the stock in a research report on Tuesday, March 11th. William Blair raised shares of Genmab A/S from a “market perform” rating to an “outperform” rating in a research report on Tuesday, March 11th. Leerink Partners upgraded shares of Genmab A/S from a “market perform” rating to an “outperform” rating and set a $27.00 price target on the stock in a report on Thursday, February 13th. Finally, HC Wainwright restated a “buy” rating and set a $50.00 price objective on shares of Genmab A/S in a report on Thursday, January 23rd. One analyst has rated the stock with a sell rating, three have issued a hold rating, eight have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, Genmab A/S has a consensus rating of “Moderate Buy” and an average target price of $41.33.

Genmab A/S Company Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.